| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 01/29/2014 | CN103536577A Tenofovir dipivoxil fumarate capsule and preparation method thereof |
| 01/29/2014 | CN103536572A Bacillus calmette-guerin tablet |
| 01/29/2014 | CN103536567A Thymopentin (TP-5) powder injection |
| 01/29/2014 | CN103536565A Cefuroxime sodium composition freeze-dried powder for injection |
| 01/29/2014 | CN103536564A Cefonicid sodium composition powder for injection |
| 01/29/2014 | CN103536561A Sulbactam sodium composition freeze-dried powder for injection |
| 01/29/2014 | CN103536560A Ceftezole sodium composition powder for injection |
| 01/29/2014 | CN103536559A Biapenem composition freeze-dried powder for injection |
| 01/29/2014 | CN103536558A Cefoperazone sodium composition freeze-dried powder for injection |
| 01/29/2014 | CN103536556A Pefloxacin mesylate composition freeze-dried powder for injection |
| 01/29/2014 | CN103536555A Ceftriaxone sodium composition freeze-dried powder for injection |
| 01/29/2014 | CN103536554A Ribostamycin sulfate composition freeze-dried powder for injection |
| 01/29/2014 | CN103536550A Flomoxef sodium composition freeze-dried powder for injection |
| 01/29/2014 | CN103536548A Oryzanol freeze-dried powder composition for injection, and preparation method thereof |
| 01/29/2014 | CN103536547A Roxithromycin composition freeze-dried powder for injection |
| 01/29/2014 | CN103536546A Cyclophosphamide composition freeze-dried powder for injection |
| 01/29/2014 | CN103536542A Injection-use ciprofloxacin composition lyophilized powder injection |
| 01/29/2014 | CN103536541A Clarithromycin freeze-dried injection and preparation method thereof |
| 01/29/2014 | CN103536540A Rifampin lyophilized powder and preparation method thereof |
| 01/29/2014 | CN103536536A Wettability solid dispersing powder of florfenicol composition and preparation method thereof |
| 01/29/2014 | CN103536531A Preparation method of long-acting injection containing danofloxacin mesylate |
| 01/29/2014 | CN103536530A Doxycycline hydrochloride long-acting injection and preparation method |
| 01/29/2014 | CN103536529A Ceftiofur-containing long-acting injection and preparation method |
| 01/29/2014 | CN103536524A Hair blackening and growing shampoo and preparation method thereof |
| 01/29/2014 | CN103536523A Plant hair lotion and preparation method thereof |
| 01/29/2014 | CN103536513A Beautifying and freckle and acne removing face mask |
| 01/29/2014 | CN103536497A Traditional Chinese medicinal compound collutory and preparation method thereof |
| 01/29/2014 | CN103536496A Toothpaste and preparation method thereof |
| 01/29/2014 | CN103536480A Plant sterilization skin-care bath cream |
| 01/29/2014 | CN103536479A Hair blackening shampoo |
| 01/29/2014 | CN103536451A Traditional Chinese medicine toothpaste and preparation method thereof |
| 01/29/2014 | CN103536450A Acne-removing product for external use and preparation method for effective components of acne-removing product |
| 01/29/2014 | CN103535393A Disinfectant obtained by compounding traditional Chinese medicine with bactericidal essential oil and capable of effectively killing lavender fragrance of staphylococcus aureus |
| 01/29/2014 | CN103110918B Medicine for treating upper respiratory infection |
| 01/29/2014 | CN103007047B Externally applied herbal cream for treating infantile mumps |
| 01/29/2014 | CN102988702B Navel dressing and nursing agent used for treatment after prostatectomy |
| 01/29/2014 | CN102805793B Oral Chinese medicinal pill for treating osteomyelitis |
| 01/29/2014 | CN102784232B Chinese medicine composition for treating viral influenza |
| 01/29/2014 | CN102764267B Carbomer cervical gel |
| 01/29/2014 | CN102757941B Hepatitis A virus strain HAV-ZL2012, vaccine prepared by using same and application thereof |
| 01/29/2014 | CN102743667B Quick-acting detoxifcation herpes zoster eliminating ointment |
| 01/29/2014 | CN102603891B Method for preparing tetanus human immune globulin by double virus inactivation |
| 01/29/2014 | CN102552920B Entecavir-containing medicinal composition and preparation method thereof |
| 01/29/2014 | CN102552789B Chinese medicine for treating damp-warm flu and preparation method and application thereof |
| 01/29/2014 | CN102526493B Medicine for resisting tuberculosis and preparation method thereof |
| 01/29/2014 | CN102443552B Porcine actinobacillus pleuropeumoniae ClpP protease gene-deleted strain containing no resistance marker, construction method thereof, and application thereof |
| 01/29/2014 | CN102395367B Use of nifuratel to treat infections caused by atopobium species |
| 01/29/2014 | CN102389526B Vacuum freeze-drying method of rhizoma polygonatum |
| 01/29/2014 | CN102382845B Method for producing porcine parvovirus antigen and its product |
| 01/29/2014 | CN102357144B Purslane, safflower, honeysuckle and cortex dictamni mixed powder for treating herpes zoster |
| 01/29/2014 | CN102267993B Polyhydroxy desmethyl tropane compounds and preparation method and use thereof |
| 01/28/2014 | US8637659 Mono-and disaccharide derivatives |
| 01/28/2014 | US8637569 Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
| 01/28/2014 | US8637535 Polymorphic and other crystalline forms of cis-FTC |
| 01/28/2014 | US8637533 Inhibitors of human phosphatidylinositol 3-kinase delta |
| 01/28/2014 | US8637513 Heterocycle phenyl amide T-type calcium channel antagonists |
| 01/28/2014 | US8637456 Engineered polypeptide agents for targeted broad spectrum influenza neutralization |
| 01/28/2014 | US8637305 Expression vectors encoding epitopes of target-associated antigens and methods for their design |
| 01/28/2014 | US8637297 Isolation, identification and characterization of strains with probiotic activity, from faeces of infants fed exclusively with breast milk |
| 01/28/2014 | US8637051 Compositions and methods for treatment of mucosal infections |
| 01/28/2014 | US8637043 Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof |
| 01/28/2014 | US8636993 Water-in-oil emulsions with anionic groups, compositions, and methods |
| 01/28/2014 | CA2738814C Hiv integrase inhibitors |
| 01/28/2014 | CA2735229C Combination therapy for tuberculosis |
| 01/28/2014 | CA2731766C Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| 01/28/2014 | CA2683958C Topical fungicidal agents for treating nail disorders |
| 01/28/2014 | CA2618974C Nanoemulsion compositions having anti-inflammatory activity |
| 01/28/2014 | CA2520382C Lupus antibodies for passive immunotherapy of hiv/aids |
| 01/28/2014 | CA2481799C Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
| 01/28/2014 | CA2459168C Method for the preparation of hexahydro-furo[2,3-b]furan-3-ol |
| 01/28/2014 | CA2436264C Endotoxin binding by lactic acid bacteria and bifidobacteria |
| 01/28/2014 | CA2431916C New therapeutic uses of smr1 peptides |
| 01/28/2014 | CA2430039C Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
| 01/23/2014 | WO2014015347A1 Compositions and methods for preventing infectious diseases in females |
| 01/23/2014 | WO2014015105A1 Solid forms of (r)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1h-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof |
| 01/23/2014 | WO2014014933A1 Hiv treatment with amido-substituted pyrimidinone derivatives |
| 01/23/2014 | WO2014014885A1 Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1 r,5s) -3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide |
| 01/23/2014 | WO2014014845A1 Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases |
| 01/23/2014 | WO2014014814A1 Compounds for the treatment and prevention of infections |
| 01/23/2014 | WO2014014726A1 Attenuated swine influenza vaccines and methods of making and use thereof |
| 01/23/2014 | WO2014014434A1 Preparation for the treatment of tuberculosis |
| 01/23/2014 | WO2014014384A1 Drug having an antiviral, anti-inflammatory, immuno-modulating and analgesic effect |
| 01/23/2014 | WO2014014364A1 Injectable antibiotic formulations and their methods of use |
| 01/23/2014 | WO2014014363A1 Injectable antibiotic formulations and their methods of use |
| 01/23/2014 | WO2014013664A1 Prophylactic/therapeutic agent for influenza virus infection |
| 01/23/2014 | WO2014013503A1 Viral trappers |
| 01/23/2014 | WO2014012849A1 A new crystal form of cefoperazone sodium |
| 01/23/2014 | WO2014012467A1 Diarylaniline or diarylpyridinamine compound and preparation method and medical use thereof |
| 01/23/2014 | WO2014012466A1 Compounds of diarylanilines and diarylpyridinamines, preparation method therefor, and uses thereof |
| 01/23/2014 | WO2014012172A1 Non-pathogenic f18 e. coli strain and use thereof |
| 01/23/2014 | WO2014012171A1 Anti-microbial gel formulations containing a silver (i) periodate |
| 01/23/2014 | WO2013174930A3 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| 01/23/2014 | WO2013166282A3 Methods and compositions for treating bacterial infection |
| 01/23/2014 | WO2013142377A3 Modified marek's disease virus, and vaccines made therefrom |
| 01/23/2014 | US20140024630 Method for the non-surgical treatment of lipodystrophy in a retrovirus-infected individual |
| 01/23/2014 | US20140024604 Glycopeptide phosphonate derivatives |
| 01/23/2014 | US20140023685 Bivalent vaccine for marine fish and method for making the same |
| 01/23/2014 | CA2877232A1 Prophylactic/therapeutic agent for influenza virus infection |
| 01/23/2014 | CA2875351A1 Injectable antibiotic formulations and their methods of use |
| 01/22/2014 | EP2687533A2 Acrylamide derivatives as FAB I inhibitors |